Galaxy Watches are being used to speed up medical studies and trials

Samsung has announced that it has partnered with Alcedis, a digital clinical research organization, to help improve the pace of medical research and drug development. Data from Galaxy Watches will be used for meaningful evidence for clinical trials in the medical and pharmaceutical fields.

Since smartwatches are worn by people throughout the day and the night, they can gather a lot more data than having hospital visits once every few months. However, gathering that raw data, organizing it, and analyzing it for usable medical evidence is a struggle for clinical research companies. To bridge that gap, Samsung and Alcedis are working together.

The South Korean firm will offer advanced smartwatch hardware, data from biometric sensors, and its backend technical infrastructure to Alcedis, who will then ensure the data complies with strict medical research standards, handle patient engagement, and manage the actual clinical studies. Bioelectrical Impedance Analysis (BIA), Electrodermal Activity (EDA), and medical-grade tracking for sleep apnea and atrial fibrillation (AFib) data from Galaxy Watches will also be used for research.

Researchers can set up studies much faster and gather higher-quality data remotely. It will help accelerate the development of new medicines and healthcare innovations. With this collaboration, Alcedis and Samsung aim to make medical research and clinical trials cheaper and faster.

Samsung is expected to launch at least two new smartwatches, the Galaxy Watch 9 and the Galaxy Watch Ultra 2, next month. Both devices could bring more advanced health and fitness tracking features, including hearing health and possibly non-invasive glucose monitoring.